BRIEF-Novartis Announces Data Showing Jakavi More Effective In Acute Graft-Versus-Host Disease [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
BRIEF-Novartis Announces Data Showing Jakavi More Effective In Acute Graft-Versus-Host Disease April 22 (Reuters) - Novartis AG: * NOVARTIS ANNOUNCES DATA SHOWING JAKAVI® (RUXOLITINIB) MORE EFFECTIVE THAN BEST AVAILABLE THERAPY IN ACUTE GRAFT-VERSUS-HOST DISEASE * NOVARTIS AG - RESULTS SHOW 62% OVERALL RESPONSE RATE WITH JAKAVI AT DAY 28, PRIMARY ENDPOINT OF STUDY, COMPARED TO 39% FOR BEST AVAILABLE THERAPY * NOVARTIS AG - NO NEW SAFETY SIGNALS WERE OBSERVED IN REACH2 * NOVARTIS AG - PHASE III REACH3 STUDY IN PATIENTS WITH STEROID-REFRACTORY CHRONIC GVHD IS ONGOING AND RESULTS ARE EXPECTED IN SECOND HALF OF THIS YEAR * NOVARTIS AG - RESULTS OF REACH2 REINFORCE FINDINGS OF PREVIOUSLY REPORTED PHASE II REACH1 STUDY Source text for Eikon: Further company coverage:
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NYSE:NVS) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novartis (NYSE:NVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Janux dives as gaps in prostate cancer study data worry investors [Yahoo! Finance Canada]Yahoo! Finance Canada
- Progress In Fight Against Malaria, As New Treatment Shows Promise [Forbes]Forbes
- Novartis (NYSE:NVS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NVS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website